197 - Athero-protective Properties of Plasma Lipoproteins from Brown Bears (Ursus arctos) during hibernation and active state (ID 1290) - The 88th EAS Congress

POSTER

Switch To Module

Conference Calendar
POSTER
Authors

GENERAL SEARCH
Title
Poster Number
Author
Presenter

Filter By

Select AllDeselect All
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.1 Endothelial cell function and biology21
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.2 Smooth muscle cell biology1
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.3 Macrophages in lipid metabolism and atherosclerosis6
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.4 Inflammation, immunity and infection in atherosclerosis31
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.5 Extracellular matrix and calcification5
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.6 Hormones and atherosclerosis6
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.7 Vascular biology of the arterial wall: Miscellaneous15
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.8 Atherosclerosis regression14
1. PATHOGENESIS OF ATHEROSCLEROSIS / 1.9 Imaging technology2
2. LIPIDS AND LIPOPROTEINS / 2.1 Lp(a)16
2. LIPIDS AND LIPOPROTEINS / 2.10 Modified lipoproteins6
2. LIPIDS AND LIPOPROTEINS / 2.2 TG rich lipoproteins metabolism and lipases6
2. LIPIDS AND LIPOPROTEINS / 2.3 HDL11
2. LIPIDS AND LIPOPROTEINS / 2.4 Lipoprotein receptors1
2. LIPIDS AND LIPOPROTEINS / 2.5 Bile acids3
2. LIPIDS AND LIPOPROTEINS / 2.6 Cholesterol efflux and reverse cholesterol transport5
2. LIPIDS AND LIPOPROTEINS / 2.7Lipids beyond cholesterol and triglycerides (lipidomics)8
2. LIPIDS AND LIPOPROTEINS / 2.8 Cellular lipid metabolism and lipid droplets6
2. LIPIDS AND LIPOPROTEINS / 2.9 Lipid and lipoprotein metabolism: Miscellaneous20
3. DYSLIPIDEMIA AND RISK FACTORS / 3.1 Epidemiology of cardiovascular diseases and risk factors57
3. DYSLIPIDEMIA AND RISK FACTORS / 3.10 Coagulation1
3. DYSLIPIDEMIA AND RISK FACTORS / 3.11 Gut microbiome2
3. DYSLIPIDEMIA AND RISK FACTORS / 3.12 Gene editing technology3
3. DYSLIPIDEMIA AND RISK FACTORS / 3.13 Genomics, GWAS and population genetics; Mendelian randomization12
3. DYSLIPIDEMIA AND RISK FACTORS / 3.14 Epigenetics and microRNA3
3. DYSLIPIDEMIA AND RISK FACTORS / 3.15 Gene-Environment interactions3
3. DYSLIPIDEMIA AND RISK FACTORS / 3.2 Epidemiology of dyslipidemias20
3. DYSLIPIDEMIA AND RISK FACTORS / 3.3 Diabetes, insulin sensitivity and resistance17
3. DYSLIPIDEMIA AND RISK FACTORS / 3.4 Adipose tissue homeostasis4
3. DYSLIPIDEMIA AND RISK FACTORS / 3.5 Inherited dyslipidemias35
3. DYSLIPIDEMIA AND RISK FACTORS / 3.6 Gender and cardiovascular risk12
3. DYSLIPIDEMIA AND RISK FACTORS / 3.7 Environmental risk factors6
3. DYSLIPIDEMIA AND RISK FACTORS / 3.8 Novel risk factors and biomarkers35
3. DYSLIPIDEMIA AND RISK FACTORS / 3.9 Epidemiology of socioeconomic and psychosocial risk factors4
4. CLINICAL VASCULAR DISEASE / 4.1 Coagulation and Thrombosis4
4. CLINICAL VASCULAR DISEASE / 4.10 Anti-thrombotic therapies2
4. CLINICAL VASCULAR DISEASE / 4.11 Anti-inflammatory therapies2
4. CLINICAL VASCULAR DISEASE / 4.12 Prevention and treatment of cardiovasculardisease; miscellaneous70
4. CLINICAL VASCULAR DISEASE / 4.13 New lipid lowering therapies4
4. CLINICAL VASCULAR DISEASE / 4.2 Endothelial dysfunction; Clinical assessment10
4. CLINICAL VASCULAR DISEASE / 4.3 NASH and other ectopic lipid diseases5
4. CLINICAL VASCULAR DISEASE / 4.4 Chronic kidney disease and nephropathies8
4. CLINICAL VASCULAR DISEASE / 4.5 Diabetes; macro- and microangiopathies13
4. CLINICAL VASCULAR DISEASE / 4.6 Aneurysms and other non-atherosclerotic arteriopathies6
4. CLINICAL VASCULAR DISEASE / 4.7 Nutrition, nutraceuticals7
4. CLINICAL VASCULAR DISEASE / 4.8 Bariatric surgery1
4. CLINICAL VASCULAR DISEASE / 4.9 Lipid-lowering therapies22
SaaG e-Posters: Adipose tissue biology and obesity6
SaaG e-Posters: Atherogenic lipoproteins: on prognostics and mechanisms4
SaaG e-Posters: Cellular lipid metabolism and lipid droplets7
SaaG e-Posters: Coagulation and thrombosis5
SaaG e-Posters: Coronary interventions and gastric bypass: outcome determinants5
SaaG e-Posters: Diabetes, lipid metabolism, and inflammation4
SaaG e-Posters: Diabetes: new mechanisms and life-style interventions1
SaaG e-Posters: Diet and nutrition: what should we have?4
SaaG e-Posters: Endothelial function and arterial stiffness from a clinical standpoint5
SaaG e-Posters: Extracellular matrix and calcification in the development of atherosclerosis5
SaaG e-Posters: Familial chylomicronemia and dysbetalipoproteinemias7
SaaG e-Posters: Fatty liver - how to get rid of?5
SaaG e-Posters: FH and the life-long disease burden7
SaaG e-Posters: Focus on endothelial cell biology6
SaaG e-Posters: Focus on inflammation and immunity4
SaaG e-Posters: Genetics on lipoproteins, cognition, DM2 and Alzheimer’s10
SaaG e-Posters: HDL - rise and shine?4
SaaG e-Posters: Hot spots in clinical imaging2
SaaG e-Posters: How to protect the kidneys?5
SaaG e-Posters: Hypertension, arterial calcification, and cardiovascular disease4
SaaG e-Posters: Improving risk estimation: lessons from coagulation, thrombosis, and miRNAs5
SaaG e-Posters: Improving risk estimation: population studies, proteomics, ceramides and extracellular vesicles5
SaaG e-Posters: Inflammation and immunity: clinical research6
SaaG e-Posters: Inflammation, immunity and vascular biology in clinical studies4
SaaG e-Posters: Key elements of endothelial cell function5
SaaG e-Posters: Learn the latest on Lp(a)6
SaaG e-Posters: Life-style, gender disparity, and psychosocial risk factors in CVD1
SaaG e-Posters: Linking immunity, inflammation and lipid metabolism in atherosclerosis6
SaaG e-Posters: Lipid-lowering therapies4
SaaG e-Posters: Macrophages at the crossroads of lipid and inflammatory pathways5
SaaG e-Posters: Modified lipoproteins, receptors, and bile acids3
SaaG e-Posters: New lipid-lowering therapies and advances with the current ones5
SaaG e-Posters: Novel findings in vascular biology4
SaaG e-Posters: Novel risk factors, biomarkers, and anti-inflammatory therapies4
SaaG e-Posters: Novel targets to regulate smooth muscle cells5
SaaG e-Posters: Peripheral artery disease and ischemic stroke5
SaaG e-Posters: Reaching treatment goals and optimising compliance7
SaaG e-Posters: Removing cholesterol: efflux and reverse cholesterol transport5
SaaG e-Posters: Screening for and characterising FH4
SaaG e-Posters: Smooth muscle cells and vascular remodelling5
SaaG e-Posters: Statin and anti-PCSK9 therapies4
SaaG e-Posters: The double-edged sword of inflammation and immunity5
SaaG e-Posters: The latest on FH genetics5
SaaG e-Posters: Treatment response in FH7
SaaG e-Posters: Triglycerides and lipases5
SaaG e-Posters: Vascular disease in diabetes4
SaaG e-Posters: What’s hot in vascular biology?6

Bookmarks
Sign in

Poster Grouping

197 - Athero-protective Properties of Plasma Lipoproteins from Brown Bears (Ursus arctos) during hibernation and active state (ID 1290)

SaaG e-Posters: Genetics on lipoproteins, cognition, DM2 and Alzheimer’s

197 - Athero-protective Properties of Plasma Lipoproteins from Brown Bears (Ursus arctos) during hibernation and active state (ID 1290)

Only SaaG posters should upload a MP3 file in this step.

Session Name

SaaG e-Posters: Genetics on lipoproteins, cognition, DM2 and Alzheimer’s

Presentation Topic

2.9 Lipid and lipoprotein metabolism: Miscellaneous

Presenter

Matteo Pedrelli,

Authors

Matteo Pedrelli,
Paolo Parini, Sweden
Jonas Kindberg, Norway
Jon M. Arnemo, Norway
Ingemar Björkhem, Sweden
Ulrika Aasa, Sweden
Maria Westerstahl, Sweden
Anna Walentinsson, Sweden
Katariina Öörni, Finland
Germán Camejo, Sweden
Ole Frobert, Sweden
Eva Hurt-Camejo, Sweden

Previous Poster Next Poster

Only SaaG posters should upload a MP3 file in this step.

Only SaaG posters should upload a MP3 file in this step.

Hide

Previous ePoster

191 - Rare GPR146 variants and their impact in the regulation of plasma lipid levels (ID 1011)

Next ePosters

192 - Construction of Genetic risk score of 24 variants for coronary artery disease in the Pakistani subjects (ID 195)

196 - Atherogenic Lipoproteins and Atherosclerotic Cardiovascular Disease in the Framingham Offspring Study (ID 96)

193 - Association between olfactory function and cognition in a high cardiovascular risk population: Construction of a polygenic risk score including olfactory receptor genes for Mendelian randomization. (ID 949)

194 - Type 2 diabetes and risk of Alzheimer's and vascular dementia: observational and Mendelian randomization studies in >1 million individuals. (ID 1224)

195 - Spectrum of LDLR gene mutations, causing familial hypercholesterolemia (FH) in Greece: un update. (ID 1111)

198 - Comparison of calculated LDL-C levels (Friedewald and Martin/Hopkins estimation) in atherogenic dyslipidemia condition (ID 912)

Programme and Faculty are preliminary and subject to change.
Give Feedback
© 2019 cSLIDE CTI MEETING TECHNOLOGY. All rights reserved.

Please add your email also in the body of the message in order to get a reply